In recent years, healthcare has been undergoing a subtle yet profound transformation.

Drug development is not for the faint of heart; a twist on the Hunger Games saying, “May the odds be (n)ever in your favor,” might adequately characterizes the challenge. As scientists, however, we manage these inherent risks by establishing best practices and learning from our collective successes and failures, as well as. In this field, experience truly matters.

Nomination of a clinical candidate and subsequent conduct of toxicology studies to support a first-in-human (FIH) clinical trial is an exciting milestone for sponsors! While many are highly experienced drug discovery professionals, some may have limited, or even no experience, in early clinical development, including the critical toxicology studies required to successfully support a FIH trial.

The complexities of active pharmaceutical ingredient (API) formulation, product testing, and documentation requirements can hinder the speed at which a promising drug candidate progresses to and through clinical trials.

Drug-drug interactions (DDIs) can pose significant safety risks, particularly in cardiovascular therapies, where patients are often on multiple medications. By analyzing these interactions early, we can help your studies stay on track and avoid potential regulatory roadblocks.